InvestorsHub Logo
Followers 62
Posts 7557
Boards Moderated 1
Alias Born 01/02/2003

Re: None

Thursday, 10/27/2022 8:05:01 AM

Thursday, October 27, 2022 8:05:01 AM

Post# of 426487
Quote..."Research and development expenses for the three months ended September 30, 2022 were $5.8 million, compared to $7.8 million in the corresponding period of the prior year. This decrease was primarily driven by the implementation of our cost reduction plan announced in June and was partially offset by costs incurred related to the DEVELOPMENT of a fixed-dose combination of VASCEPA with a statin"

.This is GOOD NEWS!...Is MND-2119 also in the headlights?...So many opportunities...So little cash.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News